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Background: Although cardiopulmonary exercise (CPX) testing was an established tool for predicting survival in patients with heart failure 
(HF), prognostic impact after implantation of left ventricular assist device (LVAD) was unknown.
methods: We enrolled 35 patients who had received implantation of extracorporeal pulsatile flow LVAD and received symptom-limited CPX 
testing at 87 days after the operation on median, and followed them between Feb 2005 and Aug 2014. We tried to construct novel scoring 
systems to predict mortality or future explantation. We also enrolled 45 patients with implantable continuous flow LVAD who had received 
CPX testing at 3 months after the operation to validate the scoring system.
results: Cox regression analyses demonstrated that (S1) maximal heart rate ≤100 bpm (HR 7.002), (S2) minute ventilation/carbon-dioxide 
output (VE/VCO2) Slope ≥54 (HR 7.195), and (S3) peak oxygen consumption (PVO2) ≤10 mL/kg/min (HR 5.973) significantly predicted 
5-year mortality after LVAD implantation (p<0.05 for all). The “Survival Score”, calculated by the number of positive S1-3, significantly 
stratified 5-year survival into low (0 point), intermediate (1-2 points), and high risk stratum (3 points) (94, 51, and 0%, respectively, p<0.01). 
The “Explantation Score”, which was also calculated by the number of positive E1-3 [(E1) maximal LOAD ≥51 W, (E2) VE/VCO2 Slope 
≤34, (E3) PVO2 ≥12.8 mL/kg/min], all were demonstrated to be significant predictors of future explantation by Cox regression analyses, 
significantly stratified 2-year cumulative explantation rate into low (0 point), intermediate (1-2 points), and high expectancy stratum (3 
points) (0, 29, and 89%, respectively, p<0.01). The “Survival Score” also stratified 5-year survival in 45 patients with implantable continuous 
flow LVAD (p<0.05).
conclusion:  “Survival Score” and “Explantation Score”, both calculated by postoperative symptom-limited CPX testing parameters, were 
novel tools to stratify 5-year survival and 2-year cumulative explantation expectancy after LVAD implantation.
